Navigation Links
MRSA vaccine shows promise in mouse study

enabled the team to compile a list of cell-surface antigens from diverse strains of the bacteria, many of them new targets. From that list, Schneewind and colleagues selected 19 potential vaccine targets taken from eight different strains of S. aureus.

By injecting each of the 19 target proteins into mice and measuring the immune response, they identified the four proteins that generated the strongest immune response. Two of those proteins, IsdA and IsdB, help the microbe acquire needed iron from the host's red blood cells. The other two, SdrD and SdrE, are thought to be involved in bacterial adhesion to host tissues.

When tested alone as a vaccine, each of the four proteins provided only partial or no protection. Fifty to 70 percent of mice vaccinated with one of these proteins and injected with a dose of a laboratory strain of the bacteria calculated to kill 50 percent of the mice, were still alive one week later.

When they vaccinated the mice using the combined vaccine, however, all of the mice survived. Although unvaccinated mice had clear evidence of kidney infections, the "bacterial load" in vaccinated mice was reduced "to a level below detection."

The next step was to test the vaccine's ability to protect mice from multiple bacterial strains isolated from humans. The researchers vaccinated 50 mice. Three weeks later, they injected groups of 10 with potentially lethal doses of one of five different clinical isolates.

The vaccine completely protected mice against two strains--including the virulent community-associated strain--and offered significant protection, resulting in 60- to 90-percent survival, against three other strains. All unprotected mice injected with the USA100 strain died within 36 hours, for example, but 60 percent of vaccinated mice survived injection with that strain.

"Further testing," said first author of the study Yukiko K. Stranger-Jones, a graduate student in the Schneewind
'"/>

Source:University of Chicago Medical Center


Page: 1 2 3

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MRSA vaccine shows promise mouse study

(Date:6/18/2013)... A UT Arlington environmental engineer has been awarded ... District to ensure water quality and flow in ... Project. , Andrew Kruzic, UT Arlington associate professor ... and locations to add monochloramine to the water ... the new pump stations and pipelines. Adding monochloramine ...
(Date:6/18/2013)... $12.7 million to match nine academic research groups ... explore new treatments for patients in eight disease ... schizophrenia. The collaborative pilot initiative, called Discovering New ... the National Center for Advancing Translational Sciences (NCATS) ... The process of developing a new therapeutic is ...
(Date:6/18/2013)... and 10% of breast and ovarian cancers are familial ... are attributable to inherited mutations from the parents in ... these mutations, PARP inhibitors, which are currently in clinical ... new option for personalised cancer treatment, an alternative to ... fraction of these patients generate resistance to the drug ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... the sun's heat on weather balloons largely accounts for ... dispute over the existence of global warming, according to ... National Oceanic and Atmospheric Administration (NOAA). , The report, ... direct heat of the sun on temperature probes of ...
... times and until our very own day, been considered ... every growing thing in their path. , Until now, ... were predominantly directed by prevailing winds. Now, Hebrew University ... of these grasshoppers ?namely their polarization vision -- provides ...
... Alberta research team has discovered important new information they ... arterial hypertension (PAH)--a deadly form of high blood pressure ... Therapies are currently limited for a disease that can ... years. , The researchers have shown that Survivin, a ...
Cached Biology News:Errors in the measurement of global warming corrected 2Locusts' built-in 'surface analysis' ability directs them to fly overland 2Researchers develop gene therapy to reverse pulmonary arterial hypertension 2Researchers develop gene therapy to reverse pulmonary arterial hypertension 3
(Date:6/18/2013)... , June 18, 2013 The ... (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & ... and studies the Major Market Drivers, Restraints, and Opportunities in ... , Asia-Pacific and Rest of World. ... Tables 22 Figures ...
(Date:6/18/2013)... 2013 Research and ... addition of the "Injectable Drug Delivery ... Devices [Disposables & Reusable, Fillable & Prefilled, ... Therapeutics [Diabetes & Oncology] - Global Forecasts ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ...
(Date:6/18/2013)... Inflamax Research Inc., a full service ... I-IV clinical trials, announced today that they will ... Technologies (NAET), a specialty air conditioning & environmental ... of mobile Environmental Exposure Chambers (EECs) used in ... , Inflamax Research has proprietary Next Generation ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 On June ... (CMS) released a final decision memorandum concluding that ... guide subsequent management of anti-tumor strategy, and the ... The National Oncological PET Registry (NOPR) was developed jointly ... first projects under the Coverage with Evidence Development (CED) ...
Breaking Biology Technology:Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 2WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 3
... Mo., Nov. 7 In refusing to a ... removal and replacement of its,current directors, management of ... developer and manufacturer of diagnostic products whose,American Depository ... that the preservation of their jobs and positions ...
... is an observational study undertaken to evaluate the, ... freezing) techniques, ROCKLAND, Mass., Nov. 7 /PRNewswire/-- ... Darmstadt, Germany, announced the launch of the Human,Oocyte ... Meeting of the American Society for Reproductive Medicine ...
... Calif., Nov. 7 AutoImmune Inc. (OTC,Bulletin Board: AIMM) today ... basic and diluted, for the three months ended September 30, ... per share basic and,diluted, for the three months ended September ... net loss was $216,000, or $0.01 per share,basic and diluted, ...
Cached Biology Technology:Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders 2Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders 3EMD Serono Launches Landmark Patient Registry for Egg Freezing 2EMD Serono Launches Landmark Patient Registry for Egg Freezing 3EMD Serono Launches Landmark Patient Registry for Egg Freezing 4AutoImmune Inc. Reports 2008 Third Quarter Financial Results 2AutoImmune Inc. Reports 2008 Third Quarter Financial Results 3
Blue Standard is 3-cyano-7-hydroxycoumarin....
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: